SavedAdd your journal

Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2014 / Cilt: 22 - Sayı: 2

Fosforilkolin kaplı ekstrakorporeal dolaşım sistemleri koagülasyon faktörlerini yetersiz düzeyde etkiler: Ön rapor

Phosphorylcholine-coated extracoporeal circulation systems affect coagulation factors during cardiopulmonary bypass insufficiently: a preliminary report

Ali Can HATEMİ
Kamil KARAOĞLU
Gürkan ÇETİN
Zafer BAŞLAR
Ali Murat MERT
Kadir ÇEVİKER
Mustafa CANİKOĞLU
Ayşem KAYA
Şahin ŞAHİNALP
Pages
334–340
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, both PC-coated or non-coated ECC systems exert similar biological effects during cardiopulmonary bypass.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: This study aims to investigate the efficacy of the phosphorylcholine (PC)-coated extracorporeal circulation (ECC) circuits compared to the non-coated ECC circuits in patients undergoing isolated coronary artery bypass grafting (CABG).
📊
Key Findings & Data:Methods: Twenty-eight patients (24 males, 4 females; mean age 62±12 years; range 41 to 84 years) who underwent elective CABG due to ischemic heart disease were enrolled in this single-blind prospective study with the odd-even number of randomization method.
💡
Conclusion & Impact:In addition, both PC-coated or non-coated ECC systems exert similar biological effects during cardiopulmonary bypass.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: This study aims to investigate the efficacy of the phosphorylcholine (PC)-coated extracorporeal circulation (ECC) circuits compared to the non-coated ECC circuits in patients undergoing isolated coronary artery bypass grafting (CABG). Methods: Twenty-eight patients (24 males, 4 females; mean age 62±12 years; range 41 to 84 years) who underwent elective CABG due to ischemic heart disease were enrolled in this single-blind prospective study with the odd-even number of randomization method. Phosphorylcholine-coated ECC systems were used in group 1 and non-coated ECC systems were used in group 2. The percentage of the coagulation factor activations [factor (F)-II, F-V, F-VII, F-VIII, F-X, F-XII, and von Willebrand factor], D-dimmer, and anti-thrombin III levels were measured preoperatively, intraoperatively and postoperatively. Results: The percentage of activation of F-II and F-X in group 1 were significantly higher than group 2 before the cross-clamp removal (T1) (p 0.05). Conclusion: Although the percentage of activation of the factors is higher in non-coated ECC systems compared to PC-coated ECC systems, it does not indicate significant clinical differences. In addition, both PC-coated or non-coated ECC systems exert similar biological effects during cardiopulmonary bypass.

Özet

Amaç: Bu çalışmada izole koroner arter baypas greftleme (KABG) yapılan hastalarda fosforilkolin (FK) kaplamalı ekstrakorporeal dolaşım (EKD) devrelerinin, kaplamasız EKD devrelerine kıyasla, etkinliği araştırıldı.Ça­lış­ma­pla­nı:­Elektif KABG'ye alınan 28 hasta (24 erkek, 4 kadın; ort. yaş 62±12 yıl; dağılım 41-84 yıl) bu tek-kör prospektif çalışma planında ve tek-çift sayı randomizasyon yöntemi ile çalışmaya dahil edildi. Fosforilkolin kaplamalı EKD sistemleri grup 1'de, kaplamasız EKD sistemleri ise grup 2'de kullanıldı. Koagülasyon faktörlerinin aktivasyon yüzdeleri [faktör (F)-II, F-V, F-VII, F-VIII, F-X, F-XII ve von Willebrand faktör], D-dimer ve antitrombin III düzeyi ameliyat öncesi, sırası ve sonrasında ölçüldü.Bul gu lar: Faktör II ve F-X aktivasyon yüzdesi kros-klemp kaldırılmadan hemen önce (T1) grup 2'de grup 1'e göre anlamlı olarak yüksekti (p 0.05).So nuç: Fosforilkolin kaplamalı EKD sistemlere kıyasla, kaplamasız EKD sistemlerinde faktör aktivasyon yüzdesi daha yüksek olmasına rağmen, anlamlı bir klinik farklılığa neden olmamaktadır. Bununla birlikte, hem FK kaplı hem de kaplamasız EKD sistemleri, kardiyopulmoner baypas sırasında benzer biyolojik etkiler sergilemektedir.

🔖

Cite This Article

HATEMİ, A. C., KARAOĞLU, K., ÇETİN, G., BAŞLAR, Z., MERT, A. M., ÇEVİKER, K., CANİKOĞLU, M., KAYA, A., ŞAHİNALP, Ş. (2022). Fosforilkolin kaplı ekstrakorporeal dolaşım sistemleri koagülasyon faktörlerini yetersiz düzeyde etkiler: Ön rapor. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 22 - Sayı: 2, 334–340. https://ajindex.com/articles/424289

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002;97:215-52.
  2. De Somer F, Van Belleghem Y, Caes F, François K, Van Overbeke H, Arnout J, et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2002;123:951-8. von Segesser LK. Surface coating of cardiopulmonary bypass circuits. Perfusion 1996;11:241-5. von Segesser LK, Tönz M, Leskosek B, Turina M. Evaluation of phospholipidic surface coatings ex-vivo. Int J Artif Organs 1994;17:294-9.
  3. De Somer F, François K, van Oeveren W, Poelaert J, De Wolf D, Ebels T, et al. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur J Cardiothorac Surg 2000;18:602-6.
  4. Ishihara K, Oshida H, Endo Y, Ueda T, Watanabe A, Nakabayashi N. Hemocompatibility of human whole blood on polymers with a phospholipid polar group and its mechanism. J Biomed Mater Res 1992;26:1543-52.
  5. Li YJ, Matthews KH, Chen TM, Wang YF, Kodama M, Nakaya T. Novel bloodcompatible polyurethanes containing poly (butadiene) soft segments and phosphatidylcholine analogues for biomedical applications. Chem Mater 1996;8:1441-50.
  6. Campbell EJ, O'Byrne V, Stratford PW, Quirk I, Vick TA, Wiles MC, et al. Biocompatible surfaces using methacryloylphosphorylcholine copolymer. ASAIO J 1994;40:M853-7. laurylmethacrylate O'Carroll-Kuehn BU, Meeran H. Management of coagulation during cardiopulmonary bypass. Contin Educ Anaesth Crit Care Pain 2007;7:195-8.
  7. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg 1998;66:2145-52. Jansen PG, te Velthuis H, Huybregts RA, Paulus R, Bulder ER, van der Spoel HI, et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. J Thorac Cardiovasc Surg 1995;110:829-34.
  8. Muedra V, Bonanad S, Gomez M, Villalonga V, Sanchez F, Lopis JE. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass. Perfusion 2011;26:487-95.
  9. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997;85:498-506.
  10. Whitten CW, Greilic